Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Investigators at Thomas Jefferson University have published new data on breast cancer
March 20th, 2008
"Vasoactive intestinal peptide and pituitary adenylate cyclase activating peptide have high affinity for VPAC1, VPAC2 and PAC1 receptors overexpressed on human cancer cells. Four potent analogues of these peptides, TP3939, TP3982, TP4200 and TP3805 were labeled with Cu-64 and evaluated ex vivo and in vivo to asses their biological activity and receptor specificity," investigators in the United States report. "The ultimate goal is to utilize Cu-64 analogues for positron emission tomography (PET) imaging of breast cancers in humans. Radiochemical purity of each analogue was > 92%. The muscle relaxivity assay revealed IC50 to be 5.3 x 10(-8) M, 4.4 x 10(-8) M, 8.1 x...
Source: Women's Health Weekly (2008-03-20)
|
